



# **Screening Libraries**

**Proteins** 

# **Product** Data Sheet

# Peucedanocoumarin III

Cat. No.: HY-122958 CAS No.: 130464-57-2 Molecular Formula:  $C_{21}H_{22}O_{7}$ 


Molecular Weight: 386.4

Target: α-synuclein

Pathway: **Neuronal Signaling** 

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



# **BIOLOGICAL ACTIVITY**

Description

Peucedanocoumarin III is an inhibitor of (alpha)-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research<sup>[1]</sup>.

## **REFERENCES**

 $[1]. Sangwoo Ham, et al. Cell-Based Screen Using Amyloid Mimic \\ \beta 23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein and Huntingtin III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as a Novel Inhibitor of \\ \alpha-Synuclein And III as$ Aggregates. Mol Cells. 2019 Jun 30;42(6):480-494.

Caution: Product has not been fully validated for medical applications. For research use only.